Articles - 4wxv mentioned but not cited (1)
- Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates. Alloy AP, Kayode O, Wang R, Hockla A, Soares AS, Radisky ES. J Biol Chem 290 21523-21535 (2015)
Reviews citing this publication (2)
- Proteases: Pivot Points in Functional Proteomics. Verhamme IM, Leonard SE, Perkins RC. Methods Mol Biol 1871 313-392 (2019)
- Is There a Trojan Horse to Aggressive Pancreatic Cancer Biology? A Review of the Trypsin-PAR2 Axis to Proliferation, Early Invasion, and Metastasis. Søreide K, Roalsø M, Aunan JR. J Pancreat Cancer 6 12-20 (2020)
Articles citing this publication (16)
- Epithelial expression and function of trypsin-3 in irritable bowel syndrome. Rolland-Fourcade C, Denadai-Souza A, Cirillo C, Lopez C, Jaramillo JO, Desormeaux C, Cenac N, Motta JP, Larauche M, Taché Y, Vanden Berghe P, Neunlist M, Coron E, Kirzin S, Portier G, Bonnet D, Alric L, Vanner S, Deraison C, Vergnolle N. Gut 66 1767-1778 (2017)
- Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy. Cohen I, Kayode O, Hockla A, Sankaran B, Radisky DC, Radisky ES, Papo N. Biochem J 473 1329-1341 (2016)
- PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma. Ma H, Hockla A, Mehner C, Coban M, Papo N, Radisky DC, Radisky ES. Sci Rep 9 1844 (2019)
- An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis. Kayode O, Wang R, Pendlebury DF, Cohen I, Henin RD, Hockla A, Soares AS, Papo N, Caulfield TR, Radisky ES. J Biol Chem 291 26304-26319 (2016)
- Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin. Cohen I, Coban M, Shahar A, Sankaran B, Hockla A, Lacham S, Caulfield TR, Radisky ES, Papo N. J Biol Chem 294 5105-5120 (2019)
- Small molecule inhibitors of mesotrypsin from a structure-based docking screen. Kayode O, Huang Z, Soares AS, Caulfield TR, Dong Z, Bode AM, Radisky ES. PLoS One 12 e0176694 (2017)
- Inactivation of mesotrypsin by chymotrypsin C prevents trypsin inhibitor degradation. Toldi V, Szabó A, Sahin-Tóth M. J Biol Chem 295 3447-3455 (2020)
- Mapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries. Naftaly S, Cohen I, Shahar A, Hockla A, Radisky ES, Papo N. Nat Commun 9 3935 (2018)
- Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases. Cohen I, Naftaly S, Ben-Zeev E, Hockla A, Radisky ES, Papo N. Biochem J 475 1335-1352 (2018)
- Climbing Up and Down Binding Landscapes through Deep Mutational Scanning of Three Homologous Protein-Protein Complexes. Heyne M, Shirian J, Cohen I, Peleg Y, Radisky ES, Papo N, Shifman JM. J Am Chem Soc 143 17261-17275 (2021)
- Elevated β-cell stress levels promote severe diabetes development in mice with MODY4. Trojanowski BM, Salem HH, Neubauer H, Simon E, Wagner M, Dorajoo R, Boehm BO, Labriola L, Wirth T, Baumann B. J Endocrinol 244 323-337 (2020)
- Potent Inhibitor of Human Trypsins from the Aeruginosin Family of Natural Products. Ahmed MN, Wahlsten M, Jokela J, Nees M, Stenman UH, Alvarenga DO, Strandin T, Sivonen K, Poso A, Permi P, Metsä-Ketelä M, Koistinen H, Fewer DP. ACS Chem Biol 16 2537-2546 (2021)
- Avidity observed between a bivalent inhibitor and an enzyme monomer with a single active site. Lacham-Hartman S, Shmidov Y, Radisky ES, Bitton R, Lukatsky DB, Papo N. PLoS One 16 e0249616 (2021)
- Evidence that the Bowman-Birk inhibitor from Pisum sativum affects intestinal proteolytic activities in chickens. Moreau T, Recoules E, De Pauw M, Labas V, Réhault-Godbert S. Poult Sci 103 103182 (2023)
- Mouse model suggests limited role for human mesotrypsin in pancreatitis. Mosztbacher D, Sahin-Tóth M. Pancreatology 21 342-352 (2021)
- Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers. Sananes A, Cohen I, Allon I, Ben-David O, Abu Shareb R, Yegodayev KM, Stepensky D, Elkabets M, Papo N. Mol Oncol 17 2337-2355 (2023)